Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Pivot Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Target Concepts:
Gene/Protein
Disease
Symptom
Drug
Enzyme
Compound
Query: UMLS:C0013421 (
dystonia
)
8,418
document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)
A YAC contig was constructed of Xq13.1 in order to sublocalize the X-linked
dystonia
-parkinsonism (XDP) syndrome locus, DYT3. The contig spans a region of approximately 1.8 Mb and includes loci DXS453/DXS348/IL2R gamma/GJB1/
CCG1
/DXS559. For the construction of the contig, nine sequence-tagged sites and four short tandem repeat polymorphisms (STRPs) were isolated. The STRPs, designated as 4704#6 (DXS7113), 4704#7 (DXS7114), 67601 (DXS7117), and B4Pst (DXS7119) were assigned to a region flanked by DXS348 proximally and by DXS559 distally. Their order was DXS348/4704 #6/4704 #7/67601/B4Pst/DXS559. They were applied to the analysis of allelic association and of haplotypes in 47 not-obviously-related XDP patients and in 105 Filipino male controls. The same haplotype was found at loci 67601 (DXS7117) and B4Pst (DXS7119) in 42 of 47 patients. This percentage of common haplotypes decreased at the adjacent loci. The findings, together with the previous demonstration of DXS559 being the distal flanking marker of DYT3, assign the disease locus to a small region in Xq13.1 defined by loci 67601 (DXS7117) and B4Pst (DXS7119). The location of DYT3 was born out by the application of a newly developed likelihood method for the analysis of linkage disequilibrium.
...
PMID:Assignment of the dystonia-parkinsonism syndrome locus, DYT3, to a small region within a 1.8-Mb YAC contig of Xq13.1. 766 93
The cause of spasmodic dysphonia, a dystonic disorder of the larynx, remains unclear. Recently,
TAFII250
, TATA-box binding protein associated factor, was suggested to be involved in
dystonia
parkinsonism. There is a possibility that
TAFII250
is involved in spasmodic dysphonia, but little information is available about the expression of
TAFII250
in the laryngeal nervous system. In this study, we investigated the localization of
TAFII250
protein in the rat laryngeal nervous system by immunohistochemistry.
TAFII250
-immunoreactivity was detected in the nodose ganglion and superior cervical ganglion. In these nuclei,
TAFII250
was localized in the nucleus of NeuroTrace-positive neurons but not in GFAP-positive glial cells. No positive cells were detected in the motor and parasympathetic nervous system.
TAFII250
-immunoreactivity was sustained between 3 and 7 days after vagotomy, but at 14 days expression was down-regulated in the distal part of the nodose ganglion. These findings suggest that
TAFII250
plays an important role in the laryngeal innervation of the sensory and sympathetic nervous systems.
...
PMID:Immunohistochemical study of TAFII250 in the rat laryngeal nervous system. 1613 84